6533b853fe1ef96bd12abf10

RESEARCH PRODUCT

Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019

Fernando CiveiraJosé López MirandaLuis MasanaJuan F. AscasoJuan Pedro-botetJosé María MostazaCarlos GuijarroXavier PintóPedro Valdivielso

subject

medicine.medical_specialtybusiness.industryGeneral EngineeringFamilial hypercholesterolemiaArteriosclerosisDiseaseEvidence-based medicinemedicine.diseaseClinical trialStable DiseasemedicineGeneral Earth and Planetary SciencesMedical prescriptionPCSK9 InhibitorsIntensive care medicinebusinessGeneral Environmental Science

description

A group of experts convened by the Spanish Society of Arteriosclerosis (SEA) has been in charge of updating the SEA document on the indications of PCSK9 inhibitors (PCSK9i) in clinical practice that was published in 2016. This update is justified by the fact that the data from clinical trials carried out on a large scale with PCSK9i have shown that in addition to their high potency to lower atherogenic cholesterol, they reduce the risk of atherosclerotic cardiovascular disease, both in patients with stable disease, and with recent disease, and with a high degree of security. This update provides the recommendations and level of evidence for the prescription of iPCSK9 in patients with homozygous and heterozygous familial hypercholesterolemia, with atherosclerotic cardiovascular disease, and in primary prevention in patients with very high cardiovascular risk. These recommendations have been established taking into account the concentration of LDL-C, the clinical situation of the patient, the additional risk factors and the cost-effectiveness of their use.

yearjournalcountryeditionlanguage
2019-05-01Clínica e Investigación en Arteriosclerosis (English Edition)
https://doi.org/10.1016/j.artere.2019.06.001